Monzosertib for relapsed or refractory blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies a new drug called monzosertib for people with certain blood cancers (AML, MDS, or CMML) that have come back or not improved after standard treatment. The goal is to see if the drug can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have AML, MDS, or CMML that has returned or not responded to treatment.
- Your cancer cells (blasts) must be at least 5% in your blood or bone marrow.
- You should be able to care for yourself (up to light activity).
- Your liver and kidneys must work well enough.
- If you've had a stem cell transplant, you must have recovered and be off immune-suppressing drugs.
- You must agree to use effective birth control during the study and for 90 days after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies a 3-drug combination to treat certain types of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) in adults. It may help by targeting cancer cells using different medicines, especially for people who may not be able to get intensive chemotherapy.
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
This trial tests two targeted drugs, ziftomenib and quizartinib, together for people with a certain type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The goal is to find the best dose and see if the combination helps.
This study tests a mix of medicines (cladribine, low-dose cytarabine, and venetoclax) alternated with azacitidine and venetoclax to treat higher-risk CMML or MDS after prior treatment or when standard treatment may not work well. It may help by improving blood counts and controlling the disease.
This Phase 1/2 trial tests a combination of medicines (decitabine/cedazuridine, venetoclax, and ivosidenib or enasidenib) in people with acute myeloid leukemia (AML) that has come back or hasn’t responded. It may help control the leukemia by targeting cancer cells and specific genetic changes in the leukemia.
This trial tests a new drug, S241656, alone or with other treatments, for people with specific types of blood cancers like acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have not responded to standard treatments or have come back.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.